Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Other

• No available paraffin-embedded tumor tissue for genomic analysis;
• Inability to collect blood for genomic evaluation.

• Women aged ≥ 18 years;
• Brazilian nationality;
• After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors \<1% and no overexpression of HER2);
• Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition;
• HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthracycline option consisting of taxane (docetaxel or paclitaxel) combined with carboplatin and trastuzumab;
• Triple-negative patients: must undergo neoadjuvant chemotherapy without immunotherapy in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel) with/ without platins (carboplatin ou cisplatin) or a regimen without anthracycline (taxane with/without platins)
• Patients must provide written informed consent prior to inclusion
• Men aged ≥ 18 years;
• Confirmed histological diagnosis of prostate adenocarcinoma;
• AJCC 8th edition clinical stage IV;
• Patients must provide written informed consent.